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cant difference, being significantly lower in the CRLZ groupIs low plasma 25-(OH)vitamin D a major risk factor for hyper-
(26 6 18 vs. 57 nmol/liter, ANOVA, P , 0.004). Plasmaparathyroidism and Looser’s zones independent of calcitriol?
25OHD was also significantly lower in the ISR group (44, P ,Background. Recent reports suggest that calcitriol might not
0.05) than in the normal x-ray group, and plasma Ca (P ,be the sole active metabolite of vitamin D and that plasma
0.003) and bicarbonate (P , 0.02) were lower. Logistical analy-concentrations of 25-(OH)vitamin D (25OHD) are often ab-
sis showed that the presence of resorption was independentlynormally low in hemodialysis patients. We have therefore eval-
linked only with plasma PTH. Looser’s zones and subperiostealuated plasma 25OHD as a risk factor for parathyroid hormone
resorption were not seen in patients with plasma 25OHD of(PTH) hypersecretion and radiological bone disease. We car-
more than 40 (Looser’s zones) and more than 100 nmol/literried out a cross-sectional study during the month of September
(subperiosteal resorption). The optimal range for intact PTHin an Algerian dialysis center of 113 patients who were not
in hemodialysis patients with mild aluminum overload is 10 totaking supplements of alphacalcidol or calcitriol.
25 pmol/liter. We found that plasma PTH was inappropriatelyMethods. Plasma 25OHD, calcitriol, PTH, calcium, phos-
high only when plasma 25OHD was less than 100 nmol/liter.phate, bicarbonate, and aluminum were measured, and x-rays
With a plasma 25OHD of between 100 and 170 nmol/liter,of the hands and pelvis were obtained for evaluation of subperi-
hypercalcemia was present with a plasma PTH of less than 10osteal resorption and Looser’s zones.
pmol/liter in only one case.Results. The median plasma 25OHD was 47.5 nmol/liter
Conclusions. This cross sectional study shows that low(range 2.5 to 170.0). Univariate analysis showed that plasma
plasma 25OHD is a major risk factor for hyperparathyroidismPTH was correlated positively with months on maintenance
and Looser’s zones. In dialysis patients, we suggest that thedialysis and negatively with plasma 25OHD, calcitriol, calcium,
plasma levels of 25OHD are maintained around the upper limitbicarbonate and aluminum, but not with that of phosphate.
of the reference range of sunny countries.plasma 25OHD was positively correlated with calcium and
calcitriol. Using multiple regression analysis, only plasma
25OHD (negative) and the duration on maintenance dialysis
(positive) were independently linked to plasma PTH. The prev- Calcitriol is well-known to be the most active of the
alence of isolated subperiosteal resorption (ISR) was 34%, vitamin D metabolites. Unfortunately, many nephrolo-and that of the combination of resorption with Looser’s zones
gists assume that it is the only active metabolite of vita-(CRLZ) was 9%; thus, only 57% of the patients had a normal
min D, so little attention is paid to the underlying vitaminx-ray appearance. These groups were comparable with regards
to age, gender, and duration on dialysis. When the biochemical D status of their patients [1, 2]. 1a-Hydroxylated deriva-
measurements of the patients with CRLZ were compared with tives of vitamin D are widely used in the dialysis patients
those from patients without radiological lesions, plasma of Western countries, but how many renal physicians mea-25OHD was the only parameter to show a statistically signifi-
sure the plasma 25-(OH)vitamin D (25OHD)? There is
a further assumption that plasma calcitriol levels are
independent of commonly prevailing levels of 25OHD [3].Key words: vitamin D, hemodialysis, parathyroid hormone, metabo-
lites, hypercalcemia. To date, only pharmacological doses of parent vitamin D
or 25OHD have been shown to increase plasma calcitriolReceived for publication May 15, 1998
levels in dialysis patients [4, 5], and this probably dependsand in revised form January 11, 1999
Accepted for publication January 13, 1999 on the synthesis of calcitriol by monocytes and macro-
phages in which the 1-hydroxylase activity is less tightly 1999 by the International Society of Nephrology
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regulated than in the kidney tubule [1]. The assumption dialysis population in which conditions were far from
ideal. The dialysis conditions were poor, and aluminum-that 1a-hydroxylated metabolites are the only active forms
containing phosphate binders, calcium salts, and allof vitamin D and the knowledge that large doses of precur-
forms of vitamin D—parent, 25-hydroxylated, andsormin D are needed to increase the production of
1-hydroxylated—were available only intermittently.calcitriol have led to a general abandonment of tradi-
tional forms of vitamin D in favor of the 1a-hydroxylated
forms. This trend has been encouraged by the knowledge METHODS
that any unintended hypercalcemia is much more easily
Patientsreversible than with parent vitamin D [6].
One hundred and thirteen uremic patients (54 menThese assumptions have now been challenged [re-
and 59 women) maintained on chronic hemodialysis atviewed in 2], and recent epidemiological studies have
the Annaba University Hospital were included in theshown a high prevalence of low 25OHD levels in older
study. Their mean age was 39 6 12 years, and their meanhealthy ambulant Europeans [7], Parisian neonates [8],
duration on dialysis was 44 6 34 months. All patientsSpanish children in winter [9], and unselected medical
were dialyzed for six hours twice per week. As verifiedin-patients in New England (USA) [10]. In the last group,
by chemical analysis, the dialysate concentration (mmol/the most important discriminator for low 25OHD levels
liter) was 1.75 for calcium, 0.75 for magnesium, and 35was whether the patients were on any form of dialysis.
for acetate. The water used for the dialysate was treatedThese individuals had hypovitaminosis D of a degree
by reverse osmosis and contained less than 0.2 mmol/less than that associated with osteomalacia. They were
liter of aluminum.not symptomatically deficient in vitamin D, but there
Most patients were prescribed oral calcium salts andwas not enough vitamin D to prevent the release of
aluminum-containing phosphate binders; however, be-regulating hormones such as parathyroid hormone
cause of the limited market availability and cost, compli-(PTH) and calcitriol, and seasonal change in bone den-
ance was poor. At the time the blood samples weresity. Classic vitamin D deficiency in association with os-
taken, for example, only one half of the patients wereteomalacia (in the absence of renal failure) usually corre-
taking their prescribed drugs. Vitamin D compounds,sponds with 25OHD levels well below the lower limit of
including alphacalcidol and calcitriol, were not pre-the reference population in western Europe, that is, 8
scribed at all.
to 10 ng/ml (20 to 25 nmol/liter) [35]. “Vitamin D insuffi-
Dietary assessment by a dietitian revealed the mean
ciency,” on the other hand, has been defined by the protein intake to be 45 g (range 20 to 112, part vegetable
plasma 25OHD being below various thresholds, all and part animal). The mean calcium intake was 428 mg
higher than those levels associated with classic defi- (range 200 to 1000), and the intake of phosphate was
ciency, as follows: 12 ng/ml (30 nmol/liter) [7–9] or 15 700 mg (range 300 to 1500).
ng/ml (37.5 nmol/liter) [10], based on the point at which
PTH secretion is stimulated; 20 ng/ml (50 nmol/liter), Radiological assessment
based on the level below which plasma calcitriol depends All patients had a plain x-ray of the hands and pelvis
on plasma 25OHD [9]; or even 40 ng/ml (100 nmol/liter), in the three months before biochemical evaluation. The
which is the level above that in Boston (MA, USA) when x-rays were independently assessed by a nephrologist
the seasonal variation in plasma PTH and bone mass in and a rheumatologist. The hand x-rays were examined
healthy postmenopausal women is abolished [11]. for evidence of hyperparathyroidism, as manifested by
In patients with renal failure, PTH secretion, calcitriol subperiosteal resorption along the radial border of the
synthesis, and bone mineral density are influenced by a phalanges, and the superior and inferior pubic rami, as
number of factors independently of plasma 25OHD lev- well as femoral necks, were examined for overt evidence
els and secondary to the uremic state. Therefore, these of osteomalacia, that is, Looser’s zones. In the event of
pathophysiological definitions are probably irrelevant in disagreement between the two assessors, a radiologist’s
dialysis patients. On the other hand, it is important to opinion was sought. Neither assessor had any knowledge
try to establish the role of plasma 25OHD in uremic of the biochemical results.
patients for both PTH hypersecretion and the genesis of
Biochemical evaluationrenal bone disease, independently of other known risk
factors including calcitriol, and the optimal range of Blood samples were taken from the patients just be-
plasma 25OHD, that is, the range associated with the fore they started their first dialysis of the week, which
lowest incidence of radiological bone lesions and lowest was during the month of September. The samples were
plasma PTH concentrations. centrifuged at once and stored at 2208C. Later, as a
It was important, therefore, to study a dialysis popula- batch, they were encased in cryogel and taken by air to
tion in which the prevalence of radiological bone disease Amiens, France for analysis.
The following measurements were made: plasma con-was likely to be high. We have studied an Algerian hemo-
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Table 1. Linear regressions
y x r N P
Plasma PTH Plasma Ca 20.25 109 50.007
Plasma PO4 10.14 113 0.14 (NS)
Plasma bicarbonate 20.19 113 50.04
Plasma 25 (OH)D 20.32 103 ,0.001
Plasma calcitriol 20.19 103 50.05
Plasma aluminium 20.24 89 50.02
Dialysis duration 10.24 113 50.016
P 25 (OH) D Plasma calcitriol 10.41 104 50.0001
Plasma Ca 10.43 100 50.0001
Plasma PO4 20.047 100 0.64 (NS)
P 1.25 (OH)2 D Plasma Ca 10.39 97 50.0001
Plasma PO4 20.03 98 0.76 (NS)
Fig. 1. Plasma 25-(OH)vitamin D (25OHD) concentration according to
radiological bony lesions. The horizontal dashed lines were drawn at
25, 40, and 100 nmol/liter. The 25 nmol/liter level corresponds to the
usual threshold below which histological osteomalacia can be seen in
the absence of renal failure, defining a vitamin D deficiency state. Forty
nmol/liter and 100 nmol/liter correspond to the thresholds above which
in this study, respectively, no Looser zones and subperiosteal resorption
are seen.
Table 2. Biochemical data according to the type of radiological lesions
Plasma Group II Group III
concentrations Group I isolated resorption
(mean6SD) Normal No lesion resorption & Looser zones P of factorial
Number of patients (%) range N565 (57) N538 (34) N510 (9) ANOVA
Intact PTH pmol/liter 1.0–5.5 22634 91 661a 96666a 0.0001
Alkaline phosphatase IU 30–117 2116189 484 6583a 3326262a 0.0025
Corrected calcium mmol/liter 2.30–2.60 2.3760.37 2.14 60.33a 2.1560.22 0.003
Phosphate mmol/liter 1.1–1.5 2.1660.77 2.15 60.67 2.0660.75 NS
Bicarbonate mmol/liter 24–28 1765 14 65a 1464 0.02
25OHD nmol/liter 25–100 57631 44 627a 26618ab 0.004
Calcitriol pmol/liter 50–150 58632 54 627 51622 NS
Aluminum lmol/liter ,0.30 1.3260.95 1.01 60.80 0.9560.52 NS
a Applicability of the ANOVA significance
b Mann-Whitney assessment of the difference between groups III and II
centration of calcium, phosphate, protein, bicarbonate, 40 ng/ml), and in the winter, it was 15 to 75 nmol/liter
(6 to 30 ng/ml); for 1,25(OH)2D, it was 50 to 150 pmol/and alkaline phosphatase by automatic analyzer SMA.
The plasma calcium (PCa) concentration was corrected liter (20 to 60 pg/ml)] [14, 15].
for the protein concentration according to Parfitt’s for-
Statistical methodsmula: [corrected PCa 5 measured total PCa/0.55 1 (protein
g/liter/160)]. Plasma concentrations of intact PTH were The determinants of plasma PTH were assessed by
univariate analysis with linear regression and by multivari-measured by a two-site immunochemiluminometric
method [12] using two specific antibodies (normal range ate analysis with multiple regression. The determinants
of the radiological lesions were first assessed by the chi-of 1.1 to 5.5 pmol/liter; Ciba Corning, Essex, UK).
Plasma concentrations of aluminum were measured by square method for qualitative parameters and by a facto-
rial analysis of variance for quantitative ones, with theinductively coupled plasma emission spectrometry (nor-
mal is less than 0.35 mmol/liter) [13]. The plasma concen- level of significance of the multicomparison being 95%
(P , 0.05). When several factors were found to be linkedtration of 25OHD and calcitriol was measured by radio-
competition methods [reference range for 25OHD in to the presence of a radiological lesion, logistical regres-
sion was used to identify the independent determinant.Paris in the late summer was 25 to 100 nmol/liter (10 to
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RESULTS
Assessment of plasma 25OHD as an independent
determinant of plasma parathyroid hormone
The median plasma 25OHD was 47.5 nmol/liter (range
2.5 to 170.0) and was comparable in men and women.
The plasma PTH concentration was positively correlated
with the duration on dialysis and negatively with the
plasma concentration of calcium, bicarbonate, 25OHD,
calcitriol, and aluminum but not correlated with that of
phosphate (Table 1). It is noteworthy that the correlation
was closer with plasma 25OHD than with plasma calci-
triol (r 5 20.32 vs. 20.19, with a P value of 0.001 vs.
0.05; Table 1).
A multiple regression analysis of plasma PTH concen-
tration was performed with the same parameters used in
Fig. 2. Plasma parathyroid hormone (PTH) versus plasma 25OHD.the linear regressions. The only independent parameters
The two horizontal dotted lines delineate the optimal range of intactshowing a statistically significant association with plasma
PTH according to Wang et al [17]. The vertical dotted line at 25 nmol/
PTH were plasma 25OHD (P , 0.005, negatively) and liter of plasma 25OHD represents the threshold often used to define
vitamin D deficiency because it is associated with osteomalacia in patientsthe duration on maintenance dialysis (P , 0.01, posi-
without renal failure. The vertical dotted line at 100 nmol/liter of plasmatively). 25OHD represents the threshold at which seasonal variations of hip bone
density is abolished (Boston) [12]. N 5 103; r 5 0.32; P 5 0.001.
Prevalence of radiological bone lesions
The radiological survey showed subperiosteal resorp-
tion in 38 patients and Looser’s zones in 10 (Table 2).
The only statistically significant difference between theFor evaluation of risk factors for these bone lesions, the
group with Looser’s zones (group III) and the two otherpatients were subdivided into three groups: group I, no
groups was the lower plasma 25OHD [26 vs. 57 (group I)bone lesions (N 5 65, 57%); group II, subperiosteal
and 44 (group II) nmol/liter].resorption alone (N 5 38, 34%); group III, both subperi-
osteal resorption and Looser’s zones (N 5 10, 9%).
Suggestions as to the optimal range for
plasma 25OHDAssessment of plasma 25OHD as a risk factor for
radiological bone lesions Figure 1 shows individual plasma 25OHD measure-
ments subdivided by radiological groups. Looser’s zonesThe three radiological groups defined previously here
(always associated with subperiosteal resorption) did notwere comparable in age, gender, and duration on dialysis.
occur with plasma 25OHD of more than 40 nmol/liter,Plasma PTH concentrations and alkaline phosphatases
and subperiosteal resorption did not occur with plasmawere elevated in all three groups, being significantly
25OHD of more than 100 nmol/liter.higher in groups II and III than in the “no-lesion” group,
Figure 2 shows the regression of plasma PTH againstbut not significantly different between groups II and
plasma 25OHD. The two horizontal dotted lines delin-III. Plasma calcium and bicarbonate concentrations were
eate the optimal range (10.0 to 25.0 pmol/liter) proposedlower in the two groups with bone lesions than in the
by Wang et al in hemodialysis patients moderately over-no-lesion group, but the difference was significant only
loaded with aluminum (positive aluminon staining be-for the group with isolated subperiosteal resorption
tween 0 and 24%) in order to have a normal bone forma-(ISR). There was no significant difference between the
tion rate [16]. All patients with plasma PTH above thegroups with and without lesions in the plasma concentra-
upper limit of this optimal range had a plasma 25OHDtions of calcitriol, phosphate, and aluminum.
of less than 100 nmol/liter. Conversely, in all patientsThe mean plasma 25OHD (nmol/liter) was lower in
with a plasma 25OHD of more than 100 nmol/liter,the two groups with bone lesions compared with the
plasma PTH was close to the optimal range.group without lesions. Logistical regression analysis in-
Figure 3 shows regression of plasma Ca against plasmacluded age, duration on dialysis, and all biochemical pa-
25OHD. Hypercalcemia above 2.70 mmol/liter was pres-rameters measured in order to evaluate any independent
ent in only one case when plasma 25OHD was aboveassociation between plasma 25OHD and subperiosteal
100 nmol/liter. The corresponding value of plasmaresorption. No independent association was found with
25OHD was 140 nmol/liter, whereas that of calcitriolplasma 25OHD, but there was an association between
subperiosteal resorption and plasma PTH (P , 0.001). was only 80 pmol/liter and that of plasma PTH was 5.5
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centrations were only weakly correlated with those of
PTH and showed no link with Looser’s zones.
Subperiosteal resorption has sometimes been associ-
ated with aluminum-induced osteomalacia, even when
histologically there is no active hyperparathyroidism.
The explanation is probably that resorption cavities of
past hyperparathyroidism become filled with osteoid that
cannot calcify, so the histological (and radiological) ab-
normalities remain until the aluminum toxicity has been
treated. In our patients, the mean plasma aluminum of
those with Looser’s zones was 0.95 mol/liter, that is,
mildly raised, but not high enough to be associated with
histological toxicity according to the data of Pei et al
[20]. Our patients were unlikely to have aluminum bone
Fig. 3. Plasma calcium versus 25OHD. The two horizontal dotted lines disease because the plasma aluminum was well below
delineate the normal range of plasma calcium. The two vertical dotted
the level for toxicity (3.7 mmol/liter), and PTH levelslines are defined in the legend of Figure 2. N 5 100; r 5 0.43; P 5 0.0001.
were not suppressed below 20 pmol/liter. Therefore, in
our patients the presence of phalangeal subperiosteal
resorption in association with Looser’s zones was on the
basis of vitamin D deficiency osteomalacia in associationpmol/liter. Hypercalcemia of 2.7 to 3.4 mmol/liter was,
with hyperparathyroidism, and not on the basis of alumi-however, present in eight cases, with a plasma 25OHD
num-induced osteomalacia.ranging from 15 to 100 nmol/liter, with normal plasma
calcitriol in all cases but one (180 pmol/liter). Plasma
Low vitamin D status as a risk factor forPTH was less than 10 pmol/liter in five patients and
hyperparathyroidism independent of calcitriolbetween 30 and 130 pmol/liter in three of these hypercal-
Subperiosteal resorption is the radiological manifesta-cemic patients.
tion of histological osteitis fibrosa related to high plasma
PTH levels, as has already been established by clinical
DISCUSSION and experimental studies [1]. It is therefore not surprising
that plasma PTH emerged as the sole independent corre-Any radiological evaluation will underestimate the
late associated with subperiosteal resorption in the logis-prevalence of renal bone disease [17] because it is known
tic regression. The negative correlation between plasmathat, although 90 to 100% of patients with end-stage
25OHD and plasma PTH is rather more surprising and,renal disease have histological evidence of renal osteo-
as far as we are aware, has not been reported before indystrophy, only 25 to 30% have evidence of subperiosteal
hemodialysis patients. Bayard et al, who first reportedresorption [18]. Nevertheless, despite the relative youth
plasma levels of 25OHD in uremic patients prior to and(39 years) of the hemodialysis patients described here
while on maintenance dialysis, only pointed to a positiveand the short time on dialysis (44 months), we have
correlation between plasma 25OHD and plasma calciumfound a large proportion of patients with radiological
levels [21]. The correlation that we observed between
bone lesions (48 out of 113; 42.5%), 10 of whom had
plasma 25OHD and plasma PTH suggests either that
Looser’s zones. This high prevalence of radiological bone high plasma PTH levels decrease 25OHD or, alterna-
disease in Annaba is reminiscent of what was observed tively, that 25OHD, either directly or indirectly, has a
when chronic dialysis first became available in Western suppressive effect on PTH secretion.
countries [19] and was anticipated as a likely conse- The possibility that high plasma PTH levels decrease
quence of underdialysis in combination with relative un- plasma 25OHD levels should be considered because in
availability and high cost of appropriate therapeutic primary hyperparathyroidism, there is an increased met-
agents. abolic clearance of 25OHD due to an increased excretion
One important finding is that low plasma 25OHD was of vitamin d-derived inactive products in the feces, which
closely associated with the presence of Looser’s zones is reversed by surgical parathyroidectomy [22]; this
and, furthermore, that plasma 25OHD was indepen- mechanism accounts much better by far for the develop-
dently and negatively correlated with plasma PTH. This ment of vitamin D deficiency in this disease than the
combination of statistical associations strongly suggests increased transformation of 25OHD3 into calcitriol [23].
that vitamin D insufficiency is at least partly responsible There is, however, no evidence from animal studies that
for both the Looser’s zones and the hyperparathyroid- either calcium or PTH has direct independent effects on
the hepatic metabolism of 25OHD [24, 25], whereasism. Interestingly, and in contrast, plasma calcitriol con-
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these studies demonstrate that calcitriol increases the than calcitriol by a factor of only 500 rather than 2400
[29]. Because its circulating concentration is 1000-foldmetabolic clearance of 25OHD and the biliary excretion
of its degradation metabolites. Furthermore, there is evi- that of calcitriol, a physiological role for 25-OHvitamin
D independent of calcitriol is eminently possible. In-dence in humans that calcitriol, but not PTH directly, is
operative in the decrease of 25OHD half-life in hyper- deed, comparing the molar potency ratio of 25-OH
vitamin D with that of calcitriol for producing a 25%parathyroidism [26]. Indeed, the 25OHD half-life was
increased in a patient with intestinal malabsorption when increase of calcium absorption in healthy humans in
whom 25-OHvitamin D3 did not increase plasma calci-large calcium supplements suppressed his secondary hy-
perparathyroidism and decreased calcitriol levels, whereas triol levels, Heaney et al found it to be approximately
1:100 [30]. These authors concluded that physiologicalin patients with postmenopausal osteoporosis, the oral
administration of 1 mg of calcitriol for four days short- plasma 25OHD levels can, on their own, account for
one-eighth of the ability to absorb calcium from the gut.ened this half-life and decreased the plasma 25OHD
levels. Because the mean plasma calcitriol levels in our An alternative explanation for the independent nega-
tive correlation between plasma PTH and plasmapatients on dialysis who received no calcitriol were near
the lower range of normal, and because their plasma 25OHD is displacement of free calcitriol from vitamin
D-binding protein when plasma 25OHD increases. Thecalcitriol levels were negatively correlated to their
plasma PTH levels but positively correlated to their finding of raised free calcitriol levels in patients with
vitamin D intoxication has been reported by Pettifor etplasma 25OHD levels, it is most unlikely that their en-
dogenous calcitriol could contribute significantly to the al [31]; however, in their cases the plasma 25OHD levels
were between 850 and 1650 nmol/liter, which is muchdecrease of their plasma 25OH levels.
Therefore, the alternative causal relationship is more higher than in our patients (all had plasma 25OHD val-
ues below 170 nmol/liter). Therefore, such a phenome-likely, and we now discuss its possible mechanisms. Be-
cause plasma 25OHD was positively correlated with cal- non is unlikely to explain the findings in our study.
Finally, a possible beneficial effect of relatively highcium and calcitriol, the negative correlation between
plasma 25OH and PTH could be explained by the known 25OHD levels on bone resorption is greater availability
of substrate for 24-hydroxylase, leading to higher plasmaindependent suppressive effects of calcitriol and calcium
on PTH synthesis [27]. However, multiple regression 24,25-(OH)2D levels [4]. It has been shown by Popovtzer
et al that 24,25-(OH)2D decreases bone resorption inanalysis showed that the negative correlation between
plasma 25OHD and plasma PTH was independent of dialysis patients independently of calcitriol [32]. This
effect could result either from a direct action on bonethe plasma concentrations of calcium and calcitriol, and
indeed of those of phosphate and aluminum. This inde- or, alternatively, by contributing to a decrease in PTH
secretion because it is known that pharmacological dosespendent negative correlation of plasma 25OHD with
plasma PTH in hemodialysis patients is in agreement of 24,25-(OH)2D3 cause a fall in PTH levels both in
dialysis patients [33] and in patients with X-linked hypo-with the negative association between plasma 25OHD
on one hand and plasma PTH and pyridinolinuria (a phosphatemic osteomalacia [34].
marker of bone resorption) on the other hand [28], which
Low vitamin D status as a risk factor for osteomalaciawas recently found in a cross-sectional study of older
men admitted for hip fracture, independent of plasma In patients maintained on chronic hemodialysis, the
most likely cause of clinical osteomalacia is aluminumfree calcitriol and free testosterone. These findings sug-
gest an effect of 25OHD (or of its metabolites other than intoxication, whether acquired from aluminum-containing
phosphate binders or from an inadequately prepared wa-calcitriol) on PTH secretion either directly or indirectly
by potentiating the effect of calcitriol. ter supply. We have already shown that aluminum is un-
likely to be etiologically relevant to the development ofSuch a hypothesis challenges the currently prevailing
concept that calcitriol is the sole active vitamin D metab- radiological bone lesions of our patients. Other hypo-
thetically important etiological possibilities are hypocal-olite that promotes intestinal absorption of calcium and
phosphate and down-regulates the transcriptional step cemia and acidosis. In this study, there was no statistically
significant difference in the plasma calcium and bicar-of PTH synthesis. Indeed, because the affinity of calci-
triol for vitamin D receptor is 2400-fold higher than that bonate between the two abnormal bone groups and the
group with no radiological abnormality. Clearly, how-of 25OHD, the 1000-times higher physiological plasma
levels of 25OHD are theoretically unable to exert any ever, the cross-sectional design of the study and the lack
of sensitivity of bone radiology mean that it is not possi-significant biological effect on their own [1, 2]. However,
recent basic research has revealed a potential physiologi- ble to definitively rule out hypocalcemia, acidosis, or
even mild aluminum overload as etiologically relevant.cal role for 25-OHvitamin D itself, independent of calci-
triol. In a whole cell transcriptional activation system, Qaw This does not diminish the value of our finding that the
one biochemical parameter to show a statistical differ-et al have shown that 25-OHvitamin D was less effective
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ence between groups was plasma 25OHD, which was above which Looser’s zones do not develop. The level
above which patients did not have Looser’s zones waslower in the group with Looser’s zones (26 nmol/liter)
than in either the group with subperiosteal resorption 40 nmol. Because the group with superiosteal resorption
on hand x-rays but without Looser’s zones also had lowalone (44 nmol/liter) or the group without any radiologi-
cal lesions (57 nmol/liter). In other words, plasma 25OHD levels (but not as low as the Looser’s zones
group), it is possible that the threshold for suppression25OHD emerges as the main risk factor for radiological
osteomalacia in these hemodialysis patients. of hyperparathyroidism is rather higher. For example,
no patient with a plasma 25OHD of more than 100 nmol/The role of vitamin D deficiency in the pathogenesis
of osteomalacia in patients with chronic renal failure liter had radiological evidence of subperiosteal resorp-
tion. Interestingly, this is the same level required to pre-(not on dialysis) was suggested by Eastwood et al, who
reported low plasma 25OHD (less than 30 nmol/liter) vent the seasonal variation of PTH and hip mineral den-
sity loss in healthy postmenopausal women [12].in patients with histologic osteomalacia compared with
those with normal bones or histological hyperparathy- All of the hemodialysis patients with a plasma 25OHD
of more than 100 nmol/liter had a plasma PTH close toroidism alone [35]. Memmos et al showed that the bones
of such patients could be cured with physiological doses the optimal range proposed by Wang et al for hemodialy-
sis patients exposed to aluminum-containing phosphateof either parent vitamin D (50 mg/day) or 25-OHvitamin
D3 (5 mg/day) for four to eight months [36]. They con- binder with a modest elevation of plasma aluminum (less
than 2 mmol/liter), as in our population [14]. There wascluded that the osteoid of patients with the osteomalacia
of chronic renal failure did not appear to show any evi- no direct correlation between plasma PO4 and plasma
25OHD, even in those with the highest levels of plasmadence of “resistance” to vitamin D. Clearly, the beneficial
effect could have been a direct one of 25OHD (or vita- 25OHD. There was a positive correlation between
plasma Ca and plasma 25OHD; however, 8% of thosemin D3), but there was the possibility that the increase
in plasma level of 25OHD simply enabled the plasma with plasma 25OHD of less than 100 nmol/liter and 10%
of those with plasma 25OHD above this level had acalcitriol to rise. In the hemodialysis patients reported
here, the calcitriol levels were not significantly different plasma Ca of more than 2.70 mmol/liter. In six of the
nine with hypercalcemia, plasma PTH was less than 10in the three groups (58, 54, and 51 pmol/liter), which
suggests that the protective effect at the bone level of pmol/liter (the lower limit of its optimal range), whereas
it was well above the optimal limit of Wang et al in thehigher plasma 25OHD levels was not mediated through
calcitriol. Perhaps the most persuasive evidence that me- other three patients (30 to 130 pmol/liter) [14]. Thus,
there is no evidence that the higher plasma 25OHDtabolites of vitamin D other than calcitriol might act
effectively on mineralization of bone is the knowledge levels were associated with higher plasma Ca or plasma
PO4 levels.that hemodialysis patients who are anephric for many
years can have bones with no histological evidence of We therefore recommend that all uremic patients, es-
pecially those on maintenance dialysis, have their plasmaosteomalacia [37].
These observations lead to the notion that 25OHD is 25-OHvitamin D periodically determined (especially at
the end of the winter), and those having a level of lessacting directly on bone mineralization. This idea is in
keeping with two histomorphometrical studies in uremic than 100 nmol/liter (40 ng/ml) should have a vitamin D
supplementation before considering therapy with 1a-patients showing that for the same elevation of plasma
calcium 3 phosphate product (or even in the face of hydroxylated forms of vitamin D, which would increase
the catabolism of 25-OHvitamin D [27]. To achieve thisa falling product), 25-OHvitamin D3 induced a greater
extension of histological mineralization than either cal- goal, we recommend a systematic oral supplement (espe-
cially from November to May in Western countries),cium carbonate with phosphate [38] or alphacalcidol [6].
The recent demonstration of the beneficial effect of rather than ultraviolet irradiation because of concerns
about skin cancer [40]. Although the recommended daily24,25-(OH)2D3 in X-linked hypophosphatemic rickets/
osteomalacia [35] brings forth a further route by which supplement of parent vitamin D has recently been in-
creased to 800 IU (20 mg) in the general older population25OHD might have a beneficial effect on the bone, be-
cause 25-OHvitamin D supplement is able to increase [40], we would rather suggest that these uremic patients
be given a double dose according to the recommenda-plasma 24,25-(OH)2D3, as shown by Halloran et al [4]
and our laboratory [39]. tions of Cunningham and Makin [2] or use the 20 to 30
mg/day dose of 25-OHvitamin D3 according to our own
Optimal vitamin D status in uremia and justification data [39]. Clearly, interventional studies are needed to
for vitamin D supplementation in uremia define the highest safe level of plasma 25OHD that
would adequately suppress PTH secretion without hy-From our data, it appears that the patients with the
lowest 25OHD levels are the ones that develop Looser’s percalcemia and the optimal dosage and periodic inter-
vals to administer the supplement, a daily administrationzones. It is possible, therefore, that there is a threshold
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Haller J, Mereiras W, van Staweren WA: Serum vitamin Dpossibly being replaced by weekly, monthly, or quarterly
concentrations in elderly in Europe. Lancet 346:207–210, 1995
administration under the supervision of a nurse in order 8. Zehgoud F, Vervel C, Guillozo H, Wabrant-Debray O, Boutig-
non H, Garabedian M: Subclinical vitamin D deficiency in neo-to increase the compliance.
nates: Definition and response to vitamin D supplements. Am JThese recommendations will be especially justified
Clin Nutr 65:771–778, 1997
when the use of new noncalcic, nonaluminic phosphate 9. Docio S, Riancho JA, Perez A, Olmos JH, Amado JA, Gonzales-
Macias J: Seasonal deficiency of vitamin D in children: A potentialbinders (such as sevelamer hydrochloride) become wide-
target for osteoporosis preventing strategies. J Bone Miner Resspread, because, like cholestyramine, they complex bili-
13:544–548, 1998
ary salts and decrease total and low-density lipoprotein 10. Thomas MK, Lloyd Jones DM, Thadam AJ, Shaw AC, Fin-
kelstein R: Hypovitaminosis D in medical inpatients. N Engl Jcholesterol and thus very likely interfere with the normal
Med 338:777–783, 1998enterohepatic cycle of vitamin D [41]. Furthermore, 11. Dawson-Hughes B, Harris S, Krall EA, Dallal GE, Falconer
these binders will decrease the needs for oral calcium G, Green CL: Rates of bone loss in post menopausal women
randomly assigned to one of two dosages of vitamin D. Am J Nutrand, therefore, increase the use of calcitriol, which will
61:1140–1145, 1995contribute to a further decrease the plasma levels of 12. Brown RC, Aston JP, Weeks I, Woodhead JS: Circulating intact
25OHD [27]. parathyroid hormone measured by a two site immunochemilumi-
nometric assay. J Clin Endocrinol Metab 65:407–414, 1987
13. Allain P, Mauras Y: Determination of aluminium in blood, urineConclusions
and water by inductively coupled plasma emission spectrometry.
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